We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Enigma Signs Licence Agreement with the UK Defence Science and Technology Laboratory
News

Enigma Signs Licence Agreement with the UK Defence Science and Technology Laboratory

Enigma Signs Licence Agreement with the UK Defence Science and Technology Laboratory
News

Enigma Signs Licence Agreement with the UK Defence Science and Technology Laboratory

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Enigma Signs Licence Agreement with the UK Defence Science and Technology Laboratory"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Enigma Diagnostics has announced that it has signed a new exclusive licence agreement with the Defence Science and Technology Laboratory (Dstl).

The worldwide licence covers a broad range of technologies, including Pyrostart, ResonSense and Temperature Control, which are important elements of Enigma’s real-time PCR systems. These PCR systems are being developed for the detection and identification of infectious organisms, such as bacteria and viruses, in clinical, environmental and biological samples. This new agreement follows the initial licence agreement that Enigma signed with Dstl in 2004.

The new licence agreement, which will remain in place until 2026, is an important development for Enigma as it will enable the Company to sub-licence any of the technologies covered by the agreement to potential partners and collaborators. The ability to sub-licence the technologies covers both PCR and non-PCR applications.

In addition, it will enable Enigma to develop its own patent portfolio, as any improvement that it makes to any of the technologies covered by this agreement will be able to be patented by the Company. As part of the agreement, Enigma will also gain ownership of a number of trademarks.

The agreement covers 25 patents and patent applications, which with effect from 13 August 2007, will be maintained and managed by Enigma. These patents were previously the responsibility of Dstl.

Advertisement